Monitor for any changes in company strategy or R&D direction following the leadership transition, though the planned nature of this departure suggests continuity. The addition of a director with commercialization experience may signal preparation for potential future product launches.
Price Chart
Executive Summary
Coya Therapeutics founder and Executive Chairman Howard Berman resigned effective April 1, 2026, as part of a planned leadership transition, with Mark H. Pavao appointed as an independent director to replace him. Berman will receive a prorated bonus, COBRA premium coverage through March 31, 2027, and extended vesting/exercise terms for stock options.
Key Facts
- Dr. Howard Berman resigned as Executive Chairman and board member effective April 1, 2026
- Resignation was part of a planned CEO transition initiated in November 2024
- Mark H. Pavao appointed as independent director effective April 1, 2026
- Berman will receive prorated 2026 bonus at 100% target
- Company will waive Berman's COBRA premiums through March 31, 2027 or until he gets other coverage
- Berman's unvested options will continue vesting for 12 months post-departure
- Vested options exercise period extended to two-year anniversary of separation date
Financial Impact
Limited financial impact with prorated bonus payment and COBRA premium coverage through March 2027
Risk Factors
- Potential loss of strategic guidance from the company founder
- Possible investor concern about leadership stability despite the planned transition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-139094 |
| Document: d104763d8k.htm | 0001193125-26-139094 |
| Document: d104763dex991.htm | 0001193125-26-139094 |
| Document: 0001193125-26-139094-index-headers.html | 0001193125-26-139094 |
| Document: 0001193125-26-139094-index.html | 0001193125-26-139094 |
| Document: 0001193125-26-139094.txt | 0001193125-26-139094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $4.18 | awaiting T+20 | — | $4.12 (−1.44%) |
Oct 5, 2026 22d ago | 8-K | $4.85 | awaiting T+20 | — | $4.12 (−15.05%) |
Sep 15, 2026 6w ago | 8-K | $4.65 $4.48 | ▼ −3.76% | ▼ −6.74% | $4.12 (−11.40%) |
Aug 11, 2026 11w ago | 8-K | $4.80 $4.61 | ▼ −3.96% | ▼ −2.90% | $4.12 (−14.17%) |
May 12, 2026 24w ago | 8-K | $4.29 $4.41 | ▲ +2.80% | ▲ +4.52% | $4.12 (−3.96%) |
Apr 2, 2026 29w ago | 8-K | $4.01 $4.23 | ▲ +5.49% | ▼ −4.39% | $4.12 (+2.74%) |
Mar 23, 2026 31w ago | EFFECT | $4.22 $4.53 | ▲ +7.35% | ▼ −0.07% | $4.12 (−2.37%) |
Mar 16, 2026 32w ago | S-3 | $4.50 $4.46 | ▼ −0.89% | ▼ −4.67% | $4.12 (−8.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers